AstraZeneca Enters $1.5 Billion License Deal for Lung Cancer Drug

AstraZeneca has entered into an exclusive license agreement with Dizal Jiangsu Pharmaceutical to acquire global rights to the lung cancer drug Zegfrovy (sunvozertinib). The deal includes a $600 million upfront payment and is expected to bolster AstraZeneca's oncology portfolio.

By Preeti Singh, SA News Editor · Seeking Alpha · July 14, 2026, 08:13 UTC

AstraZeneca Enters $1.5 Billion License Deal for Lung Cancer Drug

Tickers: $AZN

Topics: licensing agreement oncology pharmaceuticals

Read the full article at Seeking Alpha

More World news

Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC